(1S,2S)-N-benzyl-2-methylcyclopropanecarboxamide | 959774-49-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S,2S)-N-benzyl-2-methylcyclopropanecarboxamide
• 英文别名: (1S,2S)-N-benzyl-2-methylcyclopropane-1-carboxamide
• CAS: 959774-49-3
• 化学式: C₁₂H₁₅NO
• 分子量: 189.257
• InChiKey: DBMVYOYQBDNAID-ONGXEEELSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1S,2S)-N-benzyl-2-methylcyclopropanecarboxamide 在 硼烷四氢呋喃络合物 作用下， 生成 N-benzyl[(1S,2S)-2-methylcyclopropyl]methanamine
  参考文献：
  名称：

  Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation

  摘要：

  A series of low-molecular weight 2,6-diamino-isonicotinamide BACE-I inhibitors containing an amine transition-state isostere were synthesized and shown to be highly potent in both enzymatic and cell-based assays. These inhibitors contain a trans-S,S-methyl cyclopropane P-3 which bind BACE-1 in a 10s-loop down conformation giving rise to highly potent compounds with favorable molecular weight and moderate to high susceptibility to P-glycoprotein (P-gp) efflux. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.051
• 作为产物：
  描述：

  (2E)-N-benzylbut-2-enamide 在 palladium diacetate 作用下， 生成 (1S,2S)-N-benzyl-2-methylcyclopropanecarboxamide
  参考文献：
  名称：

  Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation

  摘要：

  A series of low-molecular weight 2,6-diamino-isonicotinamide BACE-I inhibitors containing an amine transition-state isostere were synthesized and shown to be highly potent in both enzymatic and cell-based assays. These inhibitors contain a trans-S,S-methyl cyclopropane P-3 which bind BACE-1 in a 10s-loop down conformation giving rise to highly potent compounds with favorable molecular weight and moderate to high susceptibility to P-glycoprotein (P-gp) efflux. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.051

文献信息

• CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170360759A1

  公开（公告）日：2017-12-21

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体、药用盐、溶剂化物或前药，其中所有变量均如本文所述。这些化合物是选择性的LPA受体抑制剂。
• LPA ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3666771A1

  公开（公告）日：2020-06-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物、药学上可接受的盐、溶液或原药，其中所有变量如本文所定义。这些化合物是选择性 LPA 受体抑制剂。
• Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10071078B2

  公开（公告）日：2018-09-11

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物、药学上可接受的盐、溶液或原药，其中所有变量如本文所定义。这些化合物是选择性 LPA 受体抑制剂。
• Discovery of Isonicotinamide Derived β-Secretase Inhibitors:  In Vivo Reduction of β-Amyloid
  作者：Matthew G. Stanton、Shaun R. Stauffer、Alison R. Gregro、Melissa Steinbeiser、Philippe Nantermet、Sethu Sankaranarayanan、Eric A. Price、Guoxin Wu、Ming-Chih Crouthamel、Joan Ellis、Ming-Tain Lai、Amy S. Espeseth、Xiao-Ping Shi、Lixia Jin、Dennis Colussi、Beth Pietrak、Qian Huang、Min Xu、Adam J. Simon、Samuel L. Graham、Joseph P. Vacca、Harold Selnick

  DOI：10.1021/jm070272d

  日期：2007.7.1

  beta-Secretase inhibition offers an exciting opportunity for therapeutic intervention in the progression of Alzheimer's disease. A series of isonicotinamides derived from traditional aspartyl protease transition state isostere inhibitors has been optimized to yield low nanomolar inhibitors with sufficient penetration across the blood-brain barrier to demonstrate beta-amyloid lowering in a murine model.